EG20218A - Process for preparing of substituted 3 aminoquinuclidines - Google Patents

Process for preparing of substituted 3 aminoquinuclidines

Info

Publication number
EG20218A
EG20218A EG27092A EG27092A EG20218A EG 20218 A EG20218 A EG 20218A EG 27092 A EG27092 A EG 27092A EG 27092 A EG27092 A EG 27092A EG 20218 A EG20218 A EG 20218A
Authority
EG
Egypt
Prior art keywords
compounds
aminoquinuclidines
substituted
preparing
disorders
Prior art date
Application number
EG27092A
Other languages
English (en)
Inventor
Pharmaceuticals Inc. Pfizer
Original Assignee
Pfizer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Pharma filed Critical Pfizer Pharma
Application granted granted Critical
Publication of EG20218A publication Critical patent/EG20218A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
EG27092A 1991-05-22 1992-05-21 Process for preparing of substituted 3 aminoquinuclidines EG20218A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14682691 1991-05-22

Publications (1)

Publication Number Publication Date
EG20218A true EG20218A (en) 1997-11-30

Family

ID=15416402

Family Applications (1)

Application Number Title Priority Date Filing Date
EG27092A EG20218A (en) 1991-05-22 1992-05-21 Process for preparing of substituted 3 aminoquinuclidines

Country Status (25)

Country Link
EP (1) EP0585328B1 (de)
KR (1) KR100246065B1 (de)
CN (1) CN1041827C (de)
AT (1) ATE211743T1 (de)
AU (1) AU658898B2 (de)
BR (1) BR9206044A (de)
CA (1) CA2109415C (de)
CZ (1) CZ247993A3 (de)
DE (2) DE69232334T2 (de)
DK (1) DK0585328T3 (de)
EG (1) EG20218A (de)
ES (1) ES2168260T3 (de)
FI (1) FI935134A7 (de)
HU (1) HUT65771A (de)
IE (1) IE921662A1 (de)
IL (1) IL101960A (de)
MX (1) MX9202449A (de)
NO (1) NO305173B1 (de)
NZ (2) NZ272941A (de)
PL (4) PL172069B1 (de)
PT (1) PT100514B (de)
RU (1) RU2092486C1 (de)
UA (1) UA26401C2 (de)
WO (1) WO1992020676A1 (de)
ZA (1) ZA923773B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
US5721255A (en) * 1992-08-19 1998-02-24 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
JP2656699B2 (ja) * 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
EP0675886B1 (de) * 1992-12-10 2000-07-05 Pfizer Inc. Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0708771B1 (de) * 1993-07-15 1998-10-07 Pfizer Inc. Benzyloxychinuclidine als substanz p antagonisten
ES2217269T3 (es) * 1993-09-17 2004-11-01 Pfizer Inc. Piperidinas 3-amino-5-carboxi sustituidas y pirrolidinas 3-amino-4-carboxi sustituidas como antagonistas de taquininas.
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0659409A3 (de) * 1993-11-23 1995-08-09 Pfizer Substanz P Antagonisten zur Hemmung der Angiogenese.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
RU2240689C1 (ru) * 2003-08-07 2004-11-27 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечерноземной зоны Российской Федерации Препарат для пастбищной профилактики фасциолеза сельскохозяйственных животных, способ его получения и применения
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2699567A1 (de) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists

Also Published As

Publication number Publication date
AU1927592A (en) 1992-12-30
ZA923773B (en) 1993-11-22
PT100514A (pt) 1993-09-30
PL170525B1 (en) 1996-12-31
WO1992020676A1 (en) 1992-11-26
DE69232334D1 (de) 2002-02-14
EP0585328B1 (de) 2002-01-09
PL172069B1 (pl) 1997-07-31
IE921662A1 (en) 1992-12-02
ES2168260T3 (es) 2002-06-16
IL101960A0 (en) 1994-04-12
AU658898B2 (en) 1995-05-04
NO934195D0 (no) 1993-11-19
DE9290057U1 (de) 1994-01-05
NZ242880A (en) 1995-10-26
ATE211743T1 (de) 2002-01-15
PT100514B (pt) 1999-06-30
MX9202449A (es) 1993-03-01
PL170513B1 (en) 1996-12-31
HUT65771A (en) 1994-07-28
KR100246065B1 (en) 2000-04-01
CN1041827C (zh) 1999-01-27
FI935134L (fi) 1993-11-19
RU2092486C1 (ru) 1997-10-10
IL101960A (en) 1999-03-12
CA2109415C (en) 1998-12-29
NZ272941A (en) 1997-05-26
FI935134A0 (fi) 1993-11-19
CN1068571A (zh) 1993-02-03
CZ247993A3 (en) 1994-07-13
UA26401C2 (uk) 1999-08-30
DE69232334T2 (de) 2002-11-14
NO934195L (no) 1993-11-19
PL171921B1 (pl) 1997-06-30
NO305173B1 (no) 1999-04-12
EP0585328A1 (de) 1994-03-09
FI935134A7 (fi) 1993-11-19
HU9303307D0 (en) 1994-03-28
BR9206044A (pt) 1995-03-01
CA2109415A1 (en) 1992-11-23
DK0585328T3 (da) 2002-02-11

Similar Documents

Publication Publication Date Title
KR100246065B1 (en) Substituted 3-aminoquinuclidines
MY107157A (en) Quinuclidine derivatives.
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
CA2102179A1 (en) Quinuclidine derivatives
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
RU93058351A (ru) Замещенные 3-аминохинуклидины, фармацевтические композиции на его основе, способы лечения, способ получения, промежуточные соединения
HUT67028A (en) Indole derivatives, pharmeceutical compositions comprising them and process for their production
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
MA22866A1 (fr) Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
HUT71127A (en) 2,3,4,5-tetrahydro-1h-3-benzodiazepines and pharmaceutically acceptable acid additional salts thereof, pharmaceutical compositions containing them and process for their preparation
ZA903944B (en) Pyrrolidone derivatives the process for their preparation and the pharmaceutical compositions containing them
HUT46921A (en) Process for producing 3-phenyl-7h-thiazolo /3,2-b//1,2,4/ triazin-7-ones, certain intermediaries thereof and pharmaceutics comprising such active ingredient
EP0522577A3 (en) Process for the preparation of pure 3,3',4,4'-tetraaminobiphenyl